Pioneering Precision Gene and RNA Therapies for a Healthier Tomorrow
Proprietary tissue-targeted delivery technology
for CNS, cartilage, muscle, and liver.
Proprietary tissue-targeted delivery technology
for CNS, cartilage, muscle, and liver.
Proprietary tissue-targeted delivery technology
for CNS, cartilage, muscle, and liver.
Proprietary tissue-targeted delivery technology
for CNS, cartilage, muscle, and liver.
Our Partnership Models
We recognise that every collaboration is unique. Dawn Therapeutics offers multiple ways to work together:
1. Co-Development Partnerships
Join forces to advance a programme from discovery to clinical stage, sharing resources, expertise, and risk.
2. Licensing Agreements
Access our proprietary delivery technology or therapeutic candidates for specific territories or indications.
3. Research Collaborations
Partner with our R&D team on target discovery, biomarker development, or preclinical model validation.
4. Manufacturing & CMC Partnerships
Leverage our scalable GMP-ready production platforms and analytics for your gene or RNA programme.
5. Advocacy & Access Partnerships
Collaborate with patient groups, NGOs, and global health organisations to improve awareness and access.
Areas of Interest
We are especially interested in partnerships for:
We are especially interested in partnerships for:
- Rare CNS disorders
- Lysosomal storage diseases
- Musculoskeletal disorders
- Orphan and ultra-orphan indications with high unmet need
- Platform technology enhancements (capsid engineering, LNP optimisation, RNA chemistry)
Areas of Interest
- Scientific Excellence – Experienced team with expertise spanning molecular biology, bioinformatics, translational medicine, and regulatory affairs.
- Regulatory Insight – Global regulatory engagement experience, including FDA, EMA, MHRA.
- Speed to Clinic – Integrated design–make–test–learn cycle to shorten timelines.
Shared Vision – Patient-centric approach embedded in every programme
How to Engage
1
2
3
Formal due diligence and partnership structuring.
4
Success Stories
Coming Soon
CNS Trial Acceleration
- 5x faster site start-up
- +38 screening-to-enrollment
- -6 ma to FPI
- Locked preview
CNS Trial Acceleration
- 5x faster site start-up
- +38 screening-to-enrollment
- -6 ma to FPI
- Locked preview
CNS Trial Acceleration
- 5x faster site start-up
- +38 screening-to-enrollment
- -6 ma to FPI
- Locked preview
- Coming Soon — Full case studies